98 related articles for article (PubMed ID: 16613764)
41. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients.
Beal K; Allen L; Yahalom J
Cancer; 2006 Jun; 106(12):2652-6. PubMed ID: 16700039
[TBL] [Abstract][Full Text] [Related]
42. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.
García-Suárez J; Bañas H; Arribas I; De Miguel D; Pascual T; Burgaleta C
Br J Haematol; 2007 Jan; 136(2):276-85. PubMed ID: 17233819
[TBL] [Abstract][Full Text] [Related]
43. Diffuse large B-cell lymphoma involving the breast. A report of four cases.
Pisani F; Romano A; Anticoli Borza P; Marino M; Micheli A; Botti C; Petti MC
J Exp Clin Cancer Res; 2006 Jun; 25(2):277-81. PubMed ID: 16918141
[TBL] [Abstract][Full Text] [Related]
44. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ
J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935
[TBL] [Abstract][Full Text] [Related]
45. Serum interleukin-10 in acquired immunodeficiency syndrome lymphoma patients. Seroco-Hemoco Study Group.
Edelman L; Deveau C; Raphael M; Monchatre E; Gabarre J; Deville-Chabrol A; Pialoux G; Emilie D; Joab I; Galanaud P
Eur Cytokine Netw; 1996 Dec; 7(4):785-91. PubMed ID: 9010682
[TBL] [Abstract][Full Text] [Related]
46. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma.
Seymour JF; Talpaz M; Cabanillas F; Wetzler M; Kurzrock R
J Clin Oncol; 1995 Mar; 13(3):575-82. PubMed ID: 7884418
[TBL] [Abstract][Full Text] [Related]
47. Cytokine profiles in patients with newly diagnosed diffuse large B-cell lymphoma: IL-6 and IL-10 levels are associated with adverse clinical features and poor outcomes.
Bao C; Gu J; Huang X; You L; Zhou Z; Jin J
Cytokine; 2023 Sep; 169():156289. PubMed ID: 37453327
[TBL] [Abstract][Full Text] [Related]
48. Serum IL-6, IL-8, IL-10 and beta2-microglobulin in association with International Prognostic Index in diffuse large B cell lymphoma.
Duletić-Nacinović A; Stifter S; Marijić B; Lucin K; Valković T; Petranović D; Jonjić N
Tumori; 2008; 94(4):511-7. PubMed ID: 18822687
[TBL] [Abstract][Full Text] [Related]
49. Prostatic acid phosphatase: a possible diagnostic marker of intravascular large B-cell lymphoma.
Kishi Y; Kami M; Kusumi E; Mineyama T; Kato D; Hamaki T; Ueyama J; Miyakoshi S; Morinaga S; Muto Y; Taniguchi S
Haematologica; 2004 May; 89(5):ECR13. PubMed ID: 15136242
[TBL] [Abstract][Full Text] [Related]
50. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma.
Lech-Maranda E; Baseggio L; Bienvenu J; Charlot C; Berger F; Rigal D; Warzocha K; Coiffier B; Salles G
Blood; 2004 May; 103(9):3529-34. PubMed ID: 14701701
[TBL] [Abstract][Full Text] [Related]
51. Serum carbohydrate antigen 125 concentration as a superior predictor for serosal effusion at diagnosis and a prognostic factor in diffuse large B-cell lymphoma.
Wu JZ; Tian T; Huang Y; Liang JH; Miao Y; Wang L; Xu J; Qu XY; Fan L; Li JY; Xu W
Cancer Biomark; 2016 Jul; 17(2):205-12. PubMed ID: 27434288
[TBL] [Abstract][Full Text] [Related]
52. Expression and Prognostic Value of PIK3CA, VEGF, IL-8, IL-10, and RIP2 in Diffuse Large B-Cell Lymphoma.
Shen N; Yu Y; Zhang R; Guo Y; Liu M; Tan M; Liu J; Bai J; Li L; Liu K; Wang R; He J
Int J Clin Pract; 2022; 2022():2637581. PubMed ID: 36567775
[TBL] [Abstract][Full Text] [Related]
53. Elevated serum IL-13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B-cell lymphoma.
Li X; Liu M; Shi Q; Fang Y; Fu D; Shen ZX; Yi H; Wang L; Zhao W
Hematol Oncol; 2023 Apr; 41(2):230-238. PubMed ID: 35304777
[TBL] [Abstract][Full Text] [Related]
54. Vitreous cytokine levels.
Wolf LA; Reed GF; Buggage RR; Nussenblatt RB; Chan CC
Ophthalmology; 2003 Aug; 110(8):1671-2. PubMed ID: 12917196
[No Abstract] [Full Text] [Related]
55. [Treatment for diffuse large B cell lymphoma, advanced stage or/and low risk].
Ohmachi K
Rinsho Ketsueki; 2010 Oct; 51(10):1402-8. PubMed ID: 20962473
[No Abstract] [Full Text] [Related]
56. [Intravascular large B-cell lymphoma presenting with fever and dyspnea: a case report].
Li J; Li YJ; Zhao DQ; Jia CW; Xu N; Zeng XJ
Zhonghua Nei Ke Za Zhi; 2024 May; 63(5):499-501. PubMed ID: 38715489
[TBL] [Abstract][Full Text] [Related]
57. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation.
Gupta M; Han JJ; Stenson M; Maurer M; Wellik L; Hu G; Ziesmer S; Dogan A; Witzig TE
Blood; 2012 Mar; 119(12):2844-53. PubMed ID: 22323454
[TBL] [Abstract][Full Text] [Related]
58. B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.
Li L; Zhang J; Chen J; Xu-Monette ZY; Miao Y; Xiao M; Young KH; Wang S; Medeiros LJ; Wang M; Ford RJ; Pham LV
Blood; 2018 Oct; 132(17):1805-1817. PubMed ID: 30209121
[TBL] [Abstract][Full Text] [Related]
59. Derangements of immunological proteins in HIV-associated diffuse large B-cell lymphoma: the frequency and prognostic impact.
Vaughan J; Patel M; Suchard M; Gededzha M; Ranchod H; Howard W; Snyman T; Wiggill T
Front Cell Infect Microbiol; 2024; 14():1340096. PubMed ID: 38633747
[TBL] [Abstract][Full Text] [Related]
60. Expression of MHC II in DRG neurons attenuates paclitaxel-induced cold hypersensitivity in male and female mice.
Whitaker EE; Mecum NE; Cott RC; Goode DJ
PLoS One; 2024; 19(2):e0298396. PubMed ID: 38330029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
